Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by MyKnighton Jun 18, 2019 10:58am
61 Views
Post# 29835693

RE:RE:RE:Nice volume again today. Let's knock this .05 wall down

RE:RE:RE:Nice volume again today. Let's knock this .05 wall downAgree with you Looking4Doubles,

I was impress by the KAL-1816 and especially this line 
specifically target the alpha3 glycine pain receptor, and is at least 40-fold more potent than desoxy-cannabidiol

Looking4Doubles - (6/18/2019 10:54:41 AM) 
RE:RE:Nice volume again today. Let's knock this .05 wall down
McKnight: I added another small amount on the news as well. This is the comment I especially liked:
" KAL-1816 is the first cannabinoid pharmaceutical designed to specifically target the alpha3 glycine pain receptor, and is at least 40-fold more potent than desoxy-cannabidiol, which is a prototypic alpha3 glycine receptor agonist. looking to free up some more cash.".
 
I see the wall as a win-win for me.  The longer it's there, the longer I can add a lot of cheap shares.  I can wait !  Just glad I found this company last fall.   GLA ! !  I think we have a tiger by the tail. - Hang on for the ride










Bullboard Posts